메뉴 건너뛰기




Volumn 18, Issue SUPPL. 2, 2007, Pages

Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; PLATINUM COMPLEX;

EID: 54349092840     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm026     Document Type: Article
Times cited : (6)

References (10)
  • 1
    • 0037115426 scopus 로고    scopus 로고
    • Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small cell lung cancer: Results form a randomized phase III trial with 5 years' follow-up
    • Sundstrom S, Bremnes RM, Kaasas S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small cell lung cancer: Results form a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4665-4672.
    • (2002) J Clin Oncol , vol.20 , pp. 4665-4672
    • Sundstrom, S.1    Bremnes, R.M.2    Kaasas, S.3
  • 2
    • 0034129381 scopus 로고    scopus 로고
    • Is there a case for cisplafin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent
    • Pujol JL, Carestia L, Daures JP. Is there a case for cisplafin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83: 8-15.
    • (2000) Br J Cancer , vol.83 , pp. 8-15
    • Pujol, J.L.1    Carestia, L.2    Daures, J.P.3
  • 3
    • 0033797356 scopus 로고    scopus 로고
    • A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. European Lung Cancer Working Party (ELCWP)
    • Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. European Lung Cancer Working Party (ELCWP). Lung Cancer 2000; 30: 23-26.
    • (2000) Lung Cancer , vol.30 , pp. 23-26
    • Mascaux, C.1    Paesmans, M.2    Berghmans, T.3
  • 4
    • 0026482388 scopus 로고
    • A meta-analysis of thoracic radiotherapy for small cell lung cancer
    • Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618-1624.
    • (1992) N Engl J Med , vol.327 , pp. 1618-1624
    • Pignon, J.P.1    Arriagada, R.2    Ihde, D.C.3
  • 5
    • 0027399457 scopus 로고
    • Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer
    • Murray N, Coy P, Patter JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. J Clin Oncol 1993; 11: 336-344.
    • (1993) J Clin Oncol , vol.11 , pp. 336-344
    • Murray, N.1    Coy, P.2    Patter, J.L.3
  • 6
    • 33748445905 scopus 로고    scopus 로고
    • Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: A London Lung Cancer Group multicenter randomized clinical trials and meta-analysis
    • Spiro SG, James LE, Rudd RM et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: A London Lung Cancer Group multicenter randomized clinical trials and meta-analysis. J Clin Oncol 2006; 24: 3823-3830.
    • (2006) J Clin Oncol , vol.24 , pp. 3823-3830
    • Spiro, S.G.1    James, L.E.2    Rudd, R.M.3
  • 7
    • 27244446896 scopus 로고    scopus 로고
    • Phase III study of adjuvant vaccination with BEC2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
    • Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with BEC2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Onool 2005; 23: 6854-6864.
    • (2005) J Clin Onool , vol.23 , pp. 6854-6864
    • Giaccone, G.1    Debruyne, C.2    Felip, E.3
  • 8
    • 33644991074 scopus 로고    scopus 로고
    • Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer
    • De Ruysscher O, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 1057-1063.
    • (2006) J Clin Oncol , vol.24 , pp. 1057-1063
    • De Ruysscher, O.1    Pijls-Johannesma, M.2    Bentzen, S.M.3
  • 9
    • 0345062339 scopus 로고    scopus 로고
    • Prophylactic cranial irradiation for patents with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group
    • Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patents with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-484.
    • (1999) N Engl J Med , vol.341 , pp. 476-484
    • Auperin, A.1    Arriagada, R.2    Pignon, J.P.3
  • 10
    • 21344434845 scopus 로고    scopus 로고
    • Management of small-cell lung cancer
    • Thatcher N, Faivre-Finn C, Lorigan P. Management of small-cell lung cancer. Ann Oncol 2005; (Suppl 2): 235-239.
    • (2005) Ann Oncol , Issue.SUPPL. 2 , pp. 235-239
    • Thatcher, N.1    Faivre-Finn, C.2    Lorigan, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.